This Article Full Text Full Text (PDF) All Versions of this Article: 1535-7163.MCT-06-0543v1 6/2/450    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lansing, T. J. Articles by Cheung, M. Search for Related Content PubMed PubMed Citation Articles by Lansing, T. J. Articles by Cheung, M.

Research Articles: Therapeutics, Targets, and Development

In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1

¹ Oncology Biology, ² Assay Development, ³ Oncology Chemistry, ⁴ Translational Medicine and Genetics, GlaxoSmithKline, Research Triangle Park, North Carolina; ⁵ Clinical Research Department 8 Vaccine, GlaxoSmithKline K.K., Shibuya, Tokyo, Japan; and ⁶ Molecular Biology Unit, Department of Biosciences, Tsukuba Research Laboratories, GlaxoSmithKline K.K., Tsukuba, Ibaraki, Japan

Requests for reprints: Timothy J. Lansing, GlaxoSmithKline R & D, 5 Moore Drive, Research Triangle Park, NC 27709. Phone: 919-483-9263. E-mail: timothy.j.lansing{at}gsk.com

Abstract

Polo-like kinase 1 (PLK1) plays key roles in the regulation of mitotic progression, including mitotic entry, spindle formation, chromosome segregation, and cytokinesis. PLK1 expression and activity are strongly linked to proliferating cells. Many studies have shown that PLK1 expression is elevated in a variety of tumors, and high expression often correlates with poor prognosis. Using a variety of methods, including small-molecule inhibition of PLK1 function and/or activity, apoptosis in cancer cell lines, cell cycle arrest in normal cell lines, and antitumor activity in vivo have been observed. In the present study, we have examined the in vitro biological activity of a novel and selective thiophene benzimidazole ATP-competitive inhibitor of PLK1 and PLK3 (5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-{[2-(trifluoromethyl)-benzyl]oxy}thiophene-2-carboxamide, called compound 1). Compound 1 has low nanomolar activity against the PLK1 and PLK3 enzymes and potently inhibits the proliferation of a wide variety of tumor cell lines. In the lung adenocarcinoma cell line NCI-H460, compound 1 induces a transient G₂-M arrest, mitotic spindle defects, and a multinucleate phenotype resulting in apoptosis, whereas normal human diploid fibroblasts arrest in G₂-M and show little apoptosis. We also describe a cellular mechanistic assay that was developed to identify potent intracellular inhibitors of PLK1. In addition to its potential as a therapeutic agent for treating cancer, compound 1 is also a useful tool molecule for further investigation of the biological functions of PLK1 and PLK3. [Mol Cancer Ther 2007;6(2):450–9]

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: Present address for D.R. Duckett: Scripps Florida, Drug Discovery, 5353 Parkside Drive, Jupiter, FL 33458. Present address for G.M. Spehar: Adherex Technologies, Inc., Suite 200, 4620 Creekstone Drive, Durham, NC 27703. Present address for M. Furuta: Technical Group, Kansai Laboratory, Medibic, TRI 3F, 1-5-4 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan.

⁷ Supplementary material for this article is available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).

Received 8/31/06; revised 12/ 1/06; accepted 12/13/06.

This article has been cited by other articles:

				Y.-H. Chi, K. Haller, M. D. Ward, O. J. Semmes, Y. Li, and K.-T. Jeang Requirements for Protein Phosphorylation and the Kinase Activity of Polo-like Kinase 1 (Plk1) for the Kinetochore Function of Mitotic Arrest Deficiency Protein 1 (Mad1) J. Biol. Chem., December 19, 2008; 283(51): 35834 - 35844. [Abstract] [Full Text] [PDF]

				L.-Y. Lu, J. L. Wood, K. Minter-Dykhouse, L. Ye, T. L. Saunders, X. Yu, and J. Chen Polo-Like Kinase 1 Is Essential for Early Embryonic Development and Tumor Suppression Mol. Cell. Biol., November 15, 2008; 28(22): 6870 - 6876. [Abstract] [Full Text] [PDF]

				M. Asiedu, D. Wu, F. Matsumura, and Q. Wei Phosphorylation of MyoGEF on Thr-574 by Plk1 Promotes MyoGEF Localization to the Central Spindle J. Biol. Chem., October 17, 2008; 283(42): 28392 - 28400. [Abstract] [Full Text] [PDF]

				P. A. Bunn Jr., E. B. Haura, and J. V. Heymach Emerging Therapies for Non-small Cell Lung Cancer ASCO Educational Book, January 1, 2008; 2008(1): e5 - e14. [Abstract] [Full Text] [PDF]

				A. Santamaria, R. Neef, U. Eberspacher, K. Eis, M. Husemann, D. Mumberg, S. Prechtl, V. Schulze, G. Siemeister, L. Wortmann, et al. Use of the Novel Plk1 Inhibitor ZK-Thiazolidinone to Elucidate Functions of Plk1 in Early and Late Stages of Mitosis Mol. Biol. Cell, October 1, 2007; 18(10): 4024 - 4036. [Abstract] [Full Text] [PDF]